Site Map
-
- Home
-
- Announcements
-
- Avexa Initiates Phase 111 ATC Trial
- Avexa announces positive results of ATC 24 week data
- AVX Audio Broadcast 5 September 2007
- Avexa acquires North American rights to ATC from Shire plc
- Avexa and Target Drug sign Binding Term Sheet for CCR5 HIV Program
- Patient Recruitment for Phase 2B HIV Trial completed
- Avexa raises $9.75 million in 2006 Share Purchase Plan
- Avexa's Antibacterial Program shows systemic activity
- Avexa announces extension of Share Purchase Plan
- Presentations
- Corporate
-
- Company Overview
- Business Development
- People
-
- Board of Directors
- Executive Committee
-
- Dr Julian Chick (Chief Executive Officer)
- Dr Jonathan Coates (Chief Scientific Officer)
- Dr Susan Cox (Senior Vice President Drug Development)
- Dr John Deadman (Senior Vice President Chemistry)
- Dr David Rhodes (Senior Vice President Biology)
- Mr Alan Boyd (CFO & Company Secretary)
- Ms Shameela Dermott (Senior Vice President Clinical Operations)
- Scientific Advisory Board
- Corporate Governance
- Avexa Employee Share Option Plan
- Projects
- Clinical Trials
- News
-
- Press Releases 2008
-
- Avexa Collaborates with TargetDrug on HCV Program
- Avexa appoints US Based Non-Executive Director
- Avexa Chairman Retires
- AVX Boardroom Radio
- Avexa reports superior results in ATC Phase 11b Clinical Trial update
- Monogram Biosciences and Avexa announce exclusive collaboration
- Half Year Results 31 December 2007
- AVX Boardroom Radio
- Avexa Initiates first Phase III Sites
- Avexa Initiates Phase 111 ATC Trial
- AVX Boardroom Radio
- Avexa to present at BIO CEO and Investor Conference
- Press Releases 2007
-
- ATC demonstrates activity against emerging class resistance
- Avexa gets "green light" to progress ATC into Phase 111
- Chairman's Address AGM 2007
- Appendix 4E
- Avexa positioned to launch Phase 111 Clinical Trial of ATC
- AVX Audio Broadcast 9 August 2007
- AVX Audio Broadcast July 2007
- Avexa releases ATC Phase IIb Clinical Trial Update
- Apricitabine Clinical Trial Update
- New Director Joins Avexa Board
- Avexa Wins $4.3M Commercial Ready Grant
- Avexa Concludes Allocation following Rights Issue
- Avexa closes oversubscribed Rights Issue
- AVX Audio Broadcast
- Avexa secures CCR5 Inhibitor HIV program with TargetDrug
- ATC demonstrates broader range of activity against drug resistant HIV strains
- Avexa announces $75 million for Phase 111 program
- Boardroom Radio Broadcast
- Avexa reports positive Phase 11b result
- Avexa Announces Trading Halt
- Avexa reports substantial progress for apricitabine
- Avexa and Novasep announce signing of manufacturing agreement for ATC
- Avexa announces resignation of Dr Errol Malta Non-Executive Director
- Phase 1 trial shows ATC has potential for combination therapy with Tipranavir
- Press Releases 2006
-
- Avexa gets all clear from Phase 1 Cardiac Safety Trial
- Avexa Antibiotic is Active in Animal Proof of Concept Study
- Avexa signs exclusive licence agreement with MNLpharma
- Avexa announces Half Yearly Results
- Avexa ramps up Phase 111 preparations for AVX754
- Avexa secures US placement and announces rights issue in a $14.4 million capital raising
- Appendix 3B New Issue Announcement 3 April 2006
- Prospectus for Non-Renounceable Rights Issue 3 April 2006
- Appendix 4C Quarterly Report
- Avexa's Capital Raising Oversubscribed
- Update on Apricitabine's Development
- Avexa's strong financial position provides foundation for promising year ahead
- Update on Apricitabine's Clinical Development
- AGM CEO presentation 2006
- AGM Chairman's Address 2006
- Avexa Announces 2006 Share Purchase Plan
- Press Releases 2005
-
- Avexa begins Phase11b trial of HIV drug
- Avexa's Proposed Offer of Options to Avexa Employees
- Avexa appoints experienced Drug Development Specialist to Board
- FDA Feedback Review Positive for Avexa
- Annual General Meeting CEO Presentation
- Annual General Meeting Chairman's Address
- Avexa's Collaboration with CSIRO
- Avexa appoints New Director
- Resignation of Non Executive Director
- Avexa Annual Financial Report
- Avexa's Quarterly Cash Flow Statement
- Investor Relations
- Presentations
- FAQs
-
- Avexa Demerger
- General
- Annual Report Information
- Shareholder Information
-
- How can I obtain/request an issuer statement?
- Am I a CHESS Sponsored Holder or an Issuer Sponsored Holder?
- I do not appear to be receiving any correspondence in connection with my Avexa shares. Why?
- I do not know my HIN/SRN. How can I find out?
- What is a SRN?
- I have received an issuer statement from Computershare Investor Services Pty Ltd but it does not app
- How do I transfer securities?
- How do I buy/sell securities and shares?
- What is a HIN?
- How do I find a broker?
- What is Avexa Limited's code for the Australia Stock Exchange (ASX)?
- I am moving house and need to change my address. How do I do this?
- How do I notify Avexa of any changes of personal details such as my address, bank details, name etc?
- Will I be charged if I require a re-print of information already provided from Computershare?
- How secure is the information I provide to Avexa's share registry Computershare Investor Services?
- What is Computershare's website address?
- Contact Us
- Annual Reports
